Chronic idiopathic axonal polyneuropathy: role of abnormal glucose metabolism


Abnormal glucose metabolism, which occurs when the body has difficulty processing glucose into energy, is twice as common among patients with chronic nerve dysfunction of unknown cause than among the general population and may be a risk factor for the condition.

Many older adults experience neuropathy, some of which are characterized by symptoms of "burning feet" and other unpleasant sensations in the lower leg.


Diabetes, genetic disorders, exposure to toxic substances and a condition called amyloidosis in which extra protein-based substances accumulate in the body tissues can all cause neuropathy, but many cases do not have an easily identifiable underlying cause.
When laboratory tests cannot determine the cause, the condition is known as chronic idiopathic axonal polyneuropathy; a cause is eventually found in only 7 to 30 percent of these cases.

Charlene Hoffman-Snyder, at Mayo Clinic, Arizona, and colleagues identified 100 consecutive patients ( 60 women and 40 men ) with chronic idiopathic axonal polyneuropathy who were evaluated between January 2003 and January 2005.
Patients underwent a complete neurological evaluation and had a fasting plasma glucose test, which measures the levels of glucose in the blood after eight hours of not eating, and a two-hour oral glucose tolerance test, which determines how well the body processes glucose by drawing blood two hours after fasting patients ingest a dose of glucose. " The fasting plasma glucose level alone does not always identify patients with impaired glucose tolerance and neither does the two-hour oral glucose tolerance test always detect patients with impaired glucose metabolism," the authors write. " Both tests are, however, useful to detect hyperglycemia and the consequences of disordered glucose metabolism."

According to the two-hour oral glucose tolerance test, 62 patients ( 62 percent ) with neuropathy had abnormal fasting glucose metabolism, including 24 with undiagnosed diabetes.
The results of the current study suggest that abnormal glucose metabolism may be a risk factor for neuropathy.

" Conventional thinking among diabetologists is that diabetic polyneuropathies are the result of prolonged hyperglycemia," the authors write. " Like previous studies, this investigation supports the hypothesis that distal axonal polyneuropathies may occur in much earlier stages of abnormal glucose metabolism than previously thought. Recent studies suggest that the neuropathy associated with impaired glucose tolerance may be milder than neuropathies traditionally associated with diabetes mellitus and may be the earliest detectable sign of abnormal glucose metabolism."

Source: Archives of Neurology, 2006


XagenaMedicine_2006



Indietro

Altri articoli

The FDA ( U.S. Food and Drug Administration ) has approved Darzalex Faspro ( Daratumumab and Hyaluronidase-fihj ), a...


HELIOS-A phase 3 study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated ( ATTR )...


Full positive results from the HELIOS-A phase 3 study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment...


The role of induction therapy prior to autologous stem cell transplant ( ASCT ) in immunoglobulin light chain ( AL...


Transthyretin ( TTR ) amyloidosis is a progressive systemic disorder caused by misfolded TTR monomers that cumulatively deposit in the...


As preclinical Alzheimer's disease becomes a target for therapeutic intervention, the overlap between imaging abnormalities associated with typical ageing and...


Transthyretin amyloidosis is caused by the deposition of hepatocyte-derived transthyretin amyloid in peripheral nerves and the heart. A therapeutic approach...


A study led by researchers from the Amyloidosis Center at Boston University School of Medicine ( BUSM ) and Boston...


A study has shown that Etanercept ( Embrel ) reduces the frequency and severity of symptoms of TNF receptor-associated periodic...


The FDA ( Food and Drug Administration ) has approved a drug to help ease the suffering faced by those...